Literature DB >> 1974989

Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function.

M Shahi1, S Thom, N Poulter, P S Sever, R A Foale.   

Abstract

The effect of antihypertensive therapy on regression of left ventricular hypertrophy and left ventricular diastolic function was investigated in 25 hypertensive patients for up to 18 months after initiation of treatment. Left ventricular mass index was calculated by two-dimensional echocardiography and left ventricular diastolic function assessed by transmitral pulsed doppler ultrasound. Significant reduction in left ventricular mass index was observed after 9 months of treatment. Only 13 patients had a reduction in mass greater than the intraobserver variability of the technique. There was no change in doppler indices of left ventricular diastolic function. In 7 patients who were studied for a further 9 months after regression had occurred there was still no appreciable difference in left ventricular diastolic function. These findings indicate that there is no direct relation between left ventricular mass and abnormal left ventricular diastolic function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974989     DOI: 10.1016/0140-6736(90)92010-f

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  Diastolic function in hypertension.

Authors:  R A Phillips; J A Diamond
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 3.  Effects of exercise, diet and weight loss on high blood pressure.

Authors:  Simon L Bacon; Andrew Sherwood; Alan Hinderliter; James A Blumenthal
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 4.  Does a reduction in left ventricular hypertrophy reduce cardiovascular morbidity and mortality?

Authors:  F H Messerli; F Soria
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 5.  Hypertension and diastolic function.

Authors:  E Agabiti-Rosei; M L Muiesan
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Racial differences in cardiac structure and function in essential hypertension.

Authors:  J Mayet; M Shahi; R A Foale; N R Poulter; P S Sever; S A McG Thom
Journal:  BMJ       Date:  1994-04-16

Review 7.  Myocardial hypertrophy and its role in heart failure with preserved ejection fraction.

Authors:  Frank R Heinzel; Felix Hohendanner; Ge Jin; Simon Sedej; Frank Edelmann
Journal:  J Appl Physiol (1985)       Date:  2015-07-16

Review 8.  Deregulation of RGS2 in cardiovascular diseases.

Authors:  Sharon Tsang; Anthony Yiu-Ho Woo; Weizhong Zhu; Rui-Ping Xiao
Journal:  Front Biosci (Schol Ed)       Date:  2010-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.